These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965 [TBL] [Abstract][Full Text] [Related]
10. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200 [TBL] [Abstract][Full Text] [Related]
12. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction. González MM; Sanz-Pastor AG; Gómez RÁ; Torrecilla NB; Moreno DM; Fernández LG; Rivas AM; Guerra AL; Álvarez R; Arranz JÁ; Rodas IM; Escudero V; Sanjurjo M; Vallejo JM; Martín M; Albarrán OG Endocr Metab Immune Disord Drug Targets; 2024; 24(14):1628-1639. PubMed ID: 38362680 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS. Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X Endocrine; 2024 Oct; 86(1):342-348. PubMed ID: 38965136 [TBL] [Abstract][Full Text] [Related]
14. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245 [TBL] [Abstract][Full Text] [Related]
15. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029 [TBL] [Abstract][Full Text] [Related]
16. The side effects of immune checkpoint inhibitor therapy on the endocrine system. Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X J Endocrinol Invest; 2022 Nov; 45(11):2131-2137. PubMed ID: 35870109 [TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168 [TBL] [Abstract][Full Text] [Related]
19. Endocrine side effects of immune checkpoint inhibitors. Cardona Z; Sosman JA; Chandra S; Huang W Front Endocrinol (Lausanne); 2023; 14():1157805. PubMed ID: 37251665 [TBL] [Abstract][Full Text] [Related]
20. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]